Amgen’s Breakthrough Blincyto Clears FDA At Breakneck Pace, But With REMS Attached
This article was originally published in The Pink Sheet Daily
The big biotech’s blinatumomab gains accelerated approval to treat a rare form of ALL. The breakthrough therapy does have a REMS on serious risks and administration concerns.
You may also be interested in...
Study supporting accelerated approval for the leukemia drug satisfied an FDA written request under the Best Pharmaceuticals for Children Act.
FDA approves Biogen’s long-acting hemophilia drug Alprolix and lifts clinical hold on Curis’ cancer drug CUDC-427, but Amgen’s announcement that its melanoma vaccine T-VEC failed to improve survival clouds its chances with the agency.
Merck, Lilly, Gilead and Celgene are among the companies striking deals that involve bispecific antibodies. The novel dual-acting drugs have been in development since the 1980s with little success, yet big pharma believes they may finally be coming of age.